Abstract
The inaugural issue is introduced by several editorials:
"The Story of Precision Nanomedicine-the Journal", "Balancing Interests of Science, Scientists, and the Publishing Business", and "Improving Innovation in Nano-Healthcare Funding".
The Clinical Editor's comments on research papers:
Prec. Nanomed. 2018, Apr; 1(1):18-42.
Extracellular vesicles (EVs) are involved in various biological processes such as cargo trafficking, cell-cell communication, and signal transduction. The advances in nanotechnology have enabled researchers to utilize EVs for potential use in clinical applications, within the so-called precision medicine approach. In this review article, the authors discuss the techniques used in EV isolation in length, together with their applications in clinical diagnosis and therapeutics.
Prec. Nanomed. 2018 Apr;1(1):63-75.
Due to potential hypersensitivity reactions to nanodrugs, thorough testing is required before these drugs can be used in the clinical setting. Here the authors provide a succinct review on the use of pigs as a reliable in-vivo model for pre-clinical drug testing.
Prec. Nanomed. 2018 Apr;1(1):76-85.
One of the ways that nanoparticles are cleared in the body is via Kupffer cells. The authors of the next paper tested the role of scavenger receptor SR-AI/II in the clearance of dextran superparamagnetic iron oxide (SPIO) Feridex-IV® and dextran-coated SPIO nanoworms (SPIO NWs). Results here show that multiple pathways and mechanisms exist in nanoparticle clearance. Thus, further understanding of nanoparticle clearance would be required to prolong in vivo half-life.
Prec. Nanomed. 2018 Apr;1(1):43-62.
Liposomes have been used in clinical practice for some years, this delivery system often result in significant systemic effects due to hypersensitivity reactions, via the activation of the complement system. The authors here show good biocompatibility of Rad-PC-Rad liposomes in terms of complement activation and pro-inflammatory cytokines production in-vitro.